Findings highlight quinoline–triazole hybrid SVI08 as a preliminary lead to the further optimization as a VEGFR-2-targeted anticancer agents as well as acceptable ADMET properties and good in vivo tolerability up to 50 mg/kg.
INTRODUCTION
Angiogenesis, primarily controlled by Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2), significantly influences tumor growth and metastasis. Consequently, VEGFR-2 targeting has emerged as an important strategy for cancer treatment. Owing to their known efficacy as strong tyrosine kinase inhibitors,...
A. Yadav, Drashti Shah, Princy Desai et al.· Current Drug Targets· 0 citations
The synthesized benzoxazole hybrid compounds showed promising anticancer activity with acceptable ADMET properties; however, further structural optimization and mechanistic studies are needed to validate the molecular targets and improve safety and pharmacokinetic profiles.
Mahmoud A. Al-Sha'er, A. H. Abdullah, Almeqdad Y. Habashneh et al.· Chemistry Africa· 0 citations
Overall, this study identifies MIH-36 as a promising lead compound with a multifaceted anticancer activity profile, associated with reduced proliferation, migration, and survival of breast cancer cells, potentially through modulation of VEGFR-2-associated pathways.
Guzide Satir-Basaran, Ahmed Amleh, Antonio Curcio et al.· Bioorganic chemistry (Print)· 0 citations
This study successfully designed and synthesized a novel series of quinazoline-chalcone hybrids, creating new chemical entities to exploit potential synergistic antitumor effects and indicated promising drug-like properties and safety profiles.
Yingnuo Wang, Jurang Li, Chun-Meng Li et al.· Journal of the Serbian Chemi...· 0 citations
A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.
Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al.· Bioorganic chemistry (Print)· 0 citations
Experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.
Hazem Elkady, Aisha A. Alsfouk, E. Elkaeed et al.· Archiv der Pharmazie· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
